{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:17:30Z","timestamp":1761895050070,"version":"3.44.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["002162080","0021620807"],"award-info":[{"award-number":["002162080","0021620807"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.diabres.2010.02.017","type":"journal-article","created":{"date-parts":[[2010,3,23]],"date-time":"2010-03-23T06:34:36Z","timestamp":1269326076000},"page":"125-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Inhibition of multifunctional dipeptidyl peptidase-IV: Is there a risk of oncological and immunological adverse effects?"],"prefix":"10.1016","volume":"88","author":[{"given":"Tomas","family":"Stulc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksi","family":"Sedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2010.02.017_bib1","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.bcp.2008.07.029","article-title":"DPP4 inhibitors for diabetes\u2014what next?","volume":"76","author":"Lambeir","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.diabres.2010.02.017_bib2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in Type 2 diabetes. Systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2010.02.017_bib3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc07-0228","article-title":"Dipeptidy peptidase-4 inhibition and the treatment of Type 2 diabetes","volume":"30","author":"Drucker","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2010.02.017_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/138945009787122860","article-title":"Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 diabetes","volume":"10","author":"Gupta","year":"2009","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.diabres.2010.02.017_bib5","first-page":"253","article-title":"Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions","volume":"47","author":"Ansorge","year":"2008","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.diabres.2010.02.017_bib6","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.2741\/2787","article-title":"The role of CD26\/dipeptidyl peptidase IV in cancer","volume":"13","author":"Havre","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.diabres.2010.02.017_bib7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/138955707780059853","article-title":"CD26\/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders","volume":"7","author":"Thompson","year":"2007","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.diabres.2010.02.017_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00577838","article-title":"A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide","volume":"7","author":"Hopsu-Havu","year":"1966","journal-title":"Histochemie"},{"key":"10.1016\/j.diabres.2010.02.017_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0167-4838(01)00278-3","article-title":"Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities?","volume":"1550","author":"Sedo","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.diabres.2010.02.017_bib10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1357-2725(03)00262-0","article-title":"Dipeptidyl peptidase IV activity and\/or structure homologues (DASH) and their substrates in cancer","volume":"36","author":"Busek","year":"2004","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.diabres.2010.02.017_bib11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1517\/17530059.2.6.677","article-title":"Dipeptidyl peptidase-IV and related molecules: markers of malignancy?","volume":"2","author":"Sedo","year":"2008","journal-title":"Expert Opin. Med. Diagn."},{"key":"10.1016\/j.diabres.2010.02.017_bib12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s00262-003-0392-9","article-title":"CD26 expression determines lung metastasis in mutant F344 rats: involvement of NK cell function and soluble CD26","volume":"52","author":"Shingu","year":"2003","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.diabres.2010.02.017_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/0-387-32824-6_5","article-title":"Structure and function in dipeptidyl peptidase IV and related proteins","volume":"575","author":"Gorrell","year":"2006","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.diabres.2010.02.017_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0165-2478(97)02716-8","article-title":"Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-\u03b21 (TGF-\u03b21) in stimulated mouse splenocytes and thymocytes","volume":"58","author":"Reinhold","year":"1997","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.diabres.2010.02.017_bib15","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-009-0728-1","article-title":"On the origin of serum CD26 and its altered concentration in cancer patients","author":"Cordero","year":"2009","journal-title":"Cancer Immunol.Immunother."},{"key":"10.1016\/j.diabres.2010.02.017_bib16","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/eji.200323469","article-title":"Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen","volume":"33","author":"Yan","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.diabres.2010.02.017_bib17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.it.2008.02.010","article-title":"Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function","volume":"29","author":"Ohnuma","year":"2008","journal-title":"Trends Immunol."},{"key":"10.1016\/j.diabres.2010.02.017_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-3083.2001.00984.x","article-title":"CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes","volume":"54","author":"Gorrell","year":"2001","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.diabres.2010.02.017_bib19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0008-8749(02)00010-2","article-title":"Soluble CD26\/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate\/insulin-like growth factor II receptor","volume":"215","author":"Ikushima","year":"2002","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.diabres.2010.02.017_bib20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/ar1852","article-title":"Dipeptidyl peptidase IV activity and\/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis?","volume":"7","author":"Sedo","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.diabres.2010.02.017_bib21","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.healun.2006.05.005","article-title":"CD26\/dipeptidylpeptidase IV-targeted therapy of acute lung rejection in rats","volume":"25","author":"Jung","year":"2006","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.diabres.2010.02.017_bib22","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/0008-5472.CAN-07-1589","article-title":"Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition","volume":"68","author":"Dang","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.diabres.2010.02.017_bib23","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.2741\/2850","article-title":"The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases","volume":"13","author":"Thielitz","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.diabres.2010.02.017_bib24","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.2741\/2849","article-title":"DP IV\/CD26 APN\/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis","volume":"13","author":"Reinhold","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.diabres.2010.02.017_bib25","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.intimp.2006.09.014","article-title":"Triggering endogenous immunosuppressive mechanisms by combined targeting of dipeptidyl peptidase IV (DPIV\/CD26) and aminopeptidase N (APN\/CD13)\u2014a novel approach for the treatment of inflammatory bowel disease","volume":"6","author":"Bank","year":"2006","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.diabres.2010.02.017_bib26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/713609354","article-title":"Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV","volume":"40","author":"Anne-Marie Lambeir","year":"2003","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.diabres.2010.02.017_bib27","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.2337\/diabetes.54.10.2988","article-title":"Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9","volume":"54","author":"Lankas","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2010.02.017_bib28","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2741\/2844","article-title":"Role of CD26\/dipeptidyl peptidase IV in human T cell activation and function","volume":"13","author":"Ohnuma","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.diabres.2010.02.017_bib29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.leukres.2008.04.019","article-title":"Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure","volume":"33","author":"Focosi","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.diabres.2010.02.017_bib30","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2337\/db08-1101","article-title":"Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation","volume":"58","author":"Su-Jin Kim","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2010.02.017_bib31","unstructured":"European Public Assessment Report, Januvia\u2014Scientific Discussion, Available from http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/januvia\/H-722-en6.pdf (accessed 11 January 2009)."},{"key":"10.1016\/j.diabres.2010.02.017_bib32","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2741\/2848","article-title":"Roles of molecules involved in epithelial\/mesenchymal transition during angiogenesis","volume":"13","author":"Ghersi","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.diabres.2010.02.017_bib33","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1158\/0008-5472.CAN-05-1245","article-title":"The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices","volume":"66","author":"Ghersi","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.diabres.2010.02.017_bib34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/onc.2008.402","article-title":"Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation","volume":"28","author":"Arscott","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.diabres.2010.02.017_bib35","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.2741\/2846","article-title":"Dipeptidyl peptidase-IV enzymatic activity bearing molecules in human brain tumors\u2014good or evil?","volume":"13","author":"Busek","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.diabres.2010.02.017_bib36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/0-387-32824-6_21","article-title":"DPIV\/CD26 and FAP in cancer: a tale of contradictions","volume":"575","author":"Sulda","year":"2006","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.diabres.2010.02.017_bib37","first-page":"2753","article-title":"Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma","volume":"62","author":"Kajiyama","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.diabres.2010.02.017_bib38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1010930918055","article-title":"Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells","volume":"18","author":"Pethiyagoda","year":"2000","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.diabres.2010.02.017_bib39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1084\/jem.190.3.311","article-title":"A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells","volume":"190","author":"Wesley","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.diabres.2010.02.017_bib40","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood-2005-04-1492","article-title":"Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26\/dipeptidylpeptidase IV","volume":"107","author":"Narducci","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.diabres.2010.02.017_bib41","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/0008-5472.CAN-04-1852","article-title":"Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway","volume":"65","author":"Wesley","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.diabres.2010.02.017_bib42","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10585-008-9188-9","article-title":"CD26\/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1\/CXCL12","volume":"25","author":"Sun","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.diabres.2010.02.017_bib43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.regpep.2006.07.003","article-title":"DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells","volume":"137","author":"Masur","year":"2006","journal-title":"Regul. Pept."},{"key":"10.1016\/j.diabres.2010.02.017_bib44","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.2337\/db09-0058","article-title":"Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin","volume":"58","author":"Matveyenko","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2010.02.017_bib45","unstructured":"FDA Januvia Approval Package: Medical Review, Available from http:\/\/www.fda.gov\/cder\/foi\/nda\/2006\/021995s000_MedR.pdf (accessed 11 January 2009)."},{"key":"10.1016\/j.diabres.2010.02.017_bib46","article-title":"Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus","volume":"16","author":"Richter","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.diabres.2010.02.017_bib47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1472-6823-8-14","article-title":"Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis","volume":"8","author":"Williams-Herman","year":"2008","journal-title":"BMC Endocr. Disord."}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822710001154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822710001154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:04:21Z","timestamp":1759172661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822710001154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0168822710001154"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2010.02.017","relation":{},"ISSN":["0168-8227"],"issn-type":[{"type":"print","value":"0168-8227"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of multifunctional dipeptidyl peptidase-IV: Is there a risk of oncological and immunological adverse effects?","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2010.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}